首页 | 本学科首页   官方微博 | 高级检索  
     


Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
Authors:David I Quinn  Catherine M Tangen  Maha Hussain  Primo N Lara  Amir Goldkorn  Carol M Moinpour  Mark G Garzotto  Philip C Mack  Michael A Carducci  J Paul Monk  Przemyslaw W Twardowski  Peter J Van Veldhuizen  Neeraj Agarwal  Celestia S Higano  Nicholas J Vogelzang  Ian M Thompson
Affiliation:1. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA;2. SWOG Statistical Center, Seattle, WA, USA;3. University of Michigan, Ann Arbor, MI, USA;4. University of California at Davis, Sacramento, CA, USA;5. Portland Veterans Administration Medical Center, Portland, OR, USA;6. Johns Hopkins Kimmel Cancer Center, Baltimore, MD;7. Ohio State University, Columbus, OH, USA;8. City of Hope Medical Center, Duarte, CA, USA;9. University of Kansas, Kansas City, KS, USA;10. University of Utah, Salt Lake City, UT, USA;11. Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, and University of Washington, Seattle, WA, USA;12. US Oncology Research, Comprehensive Cancer Centers, Las Vegas, NV, USA;13. University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号